Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study
Abstract Introduction The aim of this study was to describe the management of neovascular age-related macular degeneration (nAMD) in French patients between 2008 and 2018. Methods This was a retrospective longitudinal cohort study using exhaustive nationwide health records from the French National H...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-08-01
|
| Series: | Ophthalmology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40123-023-00772-3 |
| _version_ | 1797736446731223040 |
|---|---|
| author | Catherine P. Creuzot Garcher Mayer Srour Florian Baudin Corinne Dot Sylvia Nghiem-Buffet Jean-Francois Girmens Cedric Collin Anne Ponthieux Cécile Delcourt |
| author_facet | Catherine P. Creuzot Garcher Mayer Srour Florian Baudin Corinne Dot Sylvia Nghiem-Buffet Jean-Francois Girmens Cedric Collin Anne Ponthieux Cécile Delcourt |
| author_sort | Catherine P. Creuzot Garcher |
| collection | DOAJ |
| description | Abstract Introduction The aim of this study was to describe the management of neovascular age-related macular degeneration (nAMD) in French patients between 2008 and 2018. Methods This was a retrospective longitudinal cohort study using exhaustive nationwide health records from the French National Health Information database. Enrollment criteria were adults aged ≥ 50 years, nAMD diagnosis, or reimbursement for nAMD treatments (anti-vascular epithelial growth factor [VEGF] injection or dynamic phototherapy with verteporfin). Exclusion criteria were high myopia, diagnosis of other retinal diseases, and treatments for other macular diseases (dexamethasone implant, laser). Main outcome measures were consumption of medical care and nAMD treatments per calendar year and number of years of follow-up. Results Between 2008 and 2018, we identified 342,961 patients who have been treated for nAMD. Median duration of ophthalmological follow-up exceeded 7 years (90 months). The median annual number of ophthalmology consultations decreased from nine visits in year 1 after treatment initiation to four visits from year 7 onwards. The median duration of nAMD treatment was 10.1 months for all patients, with 48.5% of patients undergoing treatment for < 1 year. Only 24.4% of patients had maintained treatment at year 11. Patients remaining under treatment had a median of four anti-VEGF treatments per year throughout the 10-year study period. Ranibizumab was the more common first-line treatment (67.5% of patients) compared to aflibercept (32.4%). About 20% of patients who initiated treatment switched treatment at least once. Conclusions LANDSCAPE provides exhaustive nationwide data on the real-world management of nAMD in France over a 10-year period. Further investigation into short treatment duration is required, especially in terms of understanding its relation to visual outcomes. |
| first_indexed | 2024-03-12T13:14:04Z |
| format | Article |
| id | doaj.art-fbb307d6243f45c289bfce5986468952 |
| institution | Directory Open Access Journal |
| issn | 2193-8245 2193-6528 |
| language | English |
| last_indexed | 2024-03-12T13:14:04Z |
| publishDate | 2023-08-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Ophthalmology and Therapy |
| spelling | doaj.art-fbb307d6243f45c289bfce59864689522023-08-27T11:11:52ZengAdis, Springer HealthcareOphthalmology and Therapy2193-82452193-65282023-08-011252687270110.1007/s40123-023-00772-3Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE StudyCatherine P. Creuzot Garcher0Mayer Srour1Florian Baudin2Corinne Dot3Sylvia Nghiem-Buffet4Jean-Francois Girmens5Cedric Collin6Anne Ponthieux7Cécile Delcourt8Department of Ophthalmology, University HospitalDepartment of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Université de Paris Est CréteilDepartment of Ophthalmology, University HospitalDepartment of Ophthalmology, Desgenettes Military HospitalCentre d’imagerie et de laserDepartment of Ophthalmology, INSERM-DGOS CIC 1423 , Centre Hospitalier National d’Ophtalmologie (CHNO) des Quinze-VingtsIQVIA FranceNovartis Pharma SASTeam LEHA, Bordeaux Population Health Research Center, UMR INSERM 1219, Université de BordeauxAbstract Introduction The aim of this study was to describe the management of neovascular age-related macular degeneration (nAMD) in French patients between 2008 and 2018. Methods This was a retrospective longitudinal cohort study using exhaustive nationwide health records from the French National Health Information database. Enrollment criteria were adults aged ≥ 50 years, nAMD diagnosis, or reimbursement for nAMD treatments (anti-vascular epithelial growth factor [VEGF] injection or dynamic phototherapy with verteporfin). Exclusion criteria were high myopia, diagnosis of other retinal diseases, and treatments for other macular diseases (dexamethasone implant, laser). Main outcome measures were consumption of medical care and nAMD treatments per calendar year and number of years of follow-up. Results Between 2008 and 2018, we identified 342,961 patients who have been treated for nAMD. Median duration of ophthalmological follow-up exceeded 7 years (90 months). The median annual number of ophthalmology consultations decreased from nine visits in year 1 after treatment initiation to four visits from year 7 onwards. The median duration of nAMD treatment was 10.1 months for all patients, with 48.5% of patients undergoing treatment for < 1 year. Only 24.4% of patients had maintained treatment at year 11. Patients remaining under treatment had a median of four anti-VEGF treatments per year throughout the 10-year study period. Ranibizumab was the more common first-line treatment (67.5% of patients) compared to aflibercept (32.4%). About 20% of patients who initiated treatment switched treatment at least once. Conclusions LANDSCAPE provides exhaustive nationwide data on the real-world management of nAMD in France over a 10-year period. Further investigation into short treatment duration is required, especially in terms of understanding its relation to visual outcomes.https://doi.org/10.1007/s40123-023-00772-3Neovascular age-related macular degenerationSystème National des Données de SantéAnti-VEGFReal-world management |
| spellingShingle | Catherine P. Creuzot Garcher Mayer Srour Florian Baudin Corinne Dot Sylvia Nghiem-Buffet Jean-Francois Girmens Cedric Collin Anne Ponthieux Cécile Delcourt Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study Ophthalmology and Therapy Neovascular age-related macular degeneration Système National des Données de Santé Anti-VEGF Real-world management |
| title | Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study |
| title_full | Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study |
| title_fullStr | Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study |
| title_full_unstemmed | Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study |
| title_short | Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study |
| title_sort | management of neovascular age related macular degeneration treatment in france from 2008 2018 the nationwide landscape study |
| topic | Neovascular age-related macular degeneration Système National des Données de Santé Anti-VEGF Real-world management |
| url | https://doi.org/10.1007/s40123-023-00772-3 |
| work_keys_str_mv | AT catherinepcreuzotgarcher managementofneovascularagerelatedmaculardegenerationtreatmentinfrancefrom20082018thenationwidelandscapestudy AT mayersrour managementofneovascularagerelatedmaculardegenerationtreatmentinfrancefrom20082018thenationwidelandscapestudy AT florianbaudin managementofneovascularagerelatedmaculardegenerationtreatmentinfrancefrom20082018thenationwidelandscapestudy AT corinnedot managementofneovascularagerelatedmaculardegenerationtreatmentinfrancefrom20082018thenationwidelandscapestudy AT sylvianghiembuffet managementofneovascularagerelatedmaculardegenerationtreatmentinfrancefrom20082018thenationwidelandscapestudy AT jeanfrancoisgirmens managementofneovascularagerelatedmaculardegenerationtreatmentinfrancefrom20082018thenationwidelandscapestudy AT cedriccollin managementofneovascularagerelatedmaculardegenerationtreatmentinfrancefrom20082018thenationwidelandscapestudy AT anneponthieux managementofneovascularagerelatedmaculardegenerationtreatmentinfrancefrom20082018thenationwidelandscapestudy AT ceciledelcourt managementofneovascularagerelatedmaculardegenerationtreatmentinfrancefrom20082018thenationwidelandscapestudy |